ALK - Five-year GRAZAX(R) Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children

HORSHOLM, Denmark, July 7, 2017 * The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs o...